Table 3.
Crude odds ratio and risk ratio of early anti-TNF therapy for 1-year outcomes in pediatric Crohn’s disease patients.
| Outcome | ORa | 95% CI | p-value | RRa | 95% CI | p-value |
|---|---|---|---|---|---|---|
| SSFR* | 3.25 | 1.76-6.00 | <0.001 | 2.95 | 1.63-5.36 | <0.001 |
| SSFR | 1.82 | 1.05-3.14 | 0.03 | 1.65 | 1.00-2.72 | 0.049 |
| SSFMI* | 6.32 | 3.37-11.85 | <0.001 | 4.67 | 2.46-8.87 | <0.001 |
| NCR | 1.65 | 0.94-2.88 | 0.08 | 1.34 | 0.91-1.97 | 0.14 |
| Mucosal healing [as estimated by MINI index] | 1.64 | 0.75-3.57 | 0.22 | 1.28 | 0.81-2.01 | 0.29 |
CRP, C-reactive protein; TNF, tumour necrosis factor; OR, odds ratio; CI, confidence interval; RR, relative risk; NCR, normal CRP remission [remission with CRP <0.5 mg/dl]; SSFR[*], sustained steroid-free remission [*without treatment intensification]; SSFMI[*], sustained steroid-free mild or inactive disease [*without treatment intensification]; MINI-index, mucosal inflammation non-invasive index.
aRatios represent the comparison of early anti-TNF therapy against no early anti-TNF therapy.